November 26th 2020, 6:30pm
Multiple studies have suggested African American men tend to have more aggressive forms of prostate cancer, but a new study suggests that may not translate to a higher risk of death.
November 24th 2020, 3:00pm
The discovery of a genetic signature that correlates with metastasis in prostate cancer could make it much easier for physicians and patients to choose treatment strategies.
November 21st 2020, 4:10pm
Authors in the Journal of Clinical Oncology discuss hypotheses on the differences in mutations and implications for treatment with PARP inhibitors.
November 20th 2020, 9:48pm
Mounting evidence is supporting the use of poly ADP-ribose polymerase (PARP) inhibitors in prostate cancer, according to a new study.
September 21st 2020, 2:16pm
Having biomarker-driven solutions in prostate cancer is important, because they have been lacking.
May 20th 2020, 11:48pm
The therapy is for patients with deleterious or suspected deleterious germline somatic homologous recombination repair (HRR) gene–mutated cancer or for those whose cancer has progressed after prior treatment with enzalutamide or abiraterone.
March 22nd 2019, 10:38pm
Germline testing at diagnosis, along with tumor testing, have the potential to identify candidates for investigational poly (ADP-ribose) polymerase (PARP) inhibitors, and updated guidelines call for their expanded use.
May 11th 2018, 12:41am
The US Preventive Services Task Force (USPSTF) recommends that men aged 55 to 69 make their own decision on whether or not to be screened periodically for prostate cancer after they have had a conversation with their physician on potential benefits and harms.
